Poor prognosis of intra‐tumoural TRBV6‐6 variants in EGFR‐mutant NSCLC: Results from the ADJUVANT‐CTONG1104 trial.

(D) Association between V 6-6J 1-3 and V 6-6J 1-6 combination based risk score and OS or disease-free survival (DFS) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients. When patients carried high frequency of V 6-6J 1-3 or V 6-6J 1-6, the application of V 6-6 antibody or other treatment options should be considered. Overall, the results indicated both V 6-6J 1-3 and V 6-6J 1-6 associated with poor OS of I EGFR i -mutant NSCLC patients. These results not only show that specific TCR rearrangements (V 6-6J 1-3 and V 6-6J 1-6) are prognostic on their own, but the optimal model with a combination of these TCRs have the greatest predictive potential for prognosis of I EGFR i -mutant NSCLC patients. [Extracted from the article]